COVID-19 Seroprevalence Study in French Guiana (EPI-COVID-POP)

February 14, 2022 updated by: Institut Pasteur
Serological surveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies in the population to assess the extent of the infection and the COVID-19 immunity of the population in French Guiana.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Serological surveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies in the population to assess the extent of the infection and the COVID-19 immunity of the population in French Guiana.

This study is a interventional study that present minimal risks and constraints.

The results of the study will allow estimation of COVID-19 virus infection, severity and attack rates, as well as inform public health responses and policy decisions in the French Guiana territory.

Study Type

Interventional

Enrollment (Actual)

3541

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • French Guiana
      • Cayenne, French Guiana
        • Centre Hospitalier Andrée Rosemon
      • Cayenne, French Guiana
        • Laboratoire de biologie méicale, Institut Pasteur de la Guyane
      • Cayenne, French Guiana
        • Laboratoires Eurofins Guyane
      • Kourou, French Guiana
        • Laboratoire de biologie médicale de Kourou
      • Saint-Laurent du Maroni, French Guiana
        • Laboratoire de biologie médicale du Centre hospitalier de Saint-Laurent du Maroni

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • ADULT
  • OLDER_ADULT
  • CHILD

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Person going to a prevention and care center or medical biology analysis laboratory as part of the care, regardless age, regardless of an acute or previous infection with COVID-19;
  • State of health compatible with a blood sample as defined in the protocol

Exclusion Criteria:

  • Inability to consent
  • Person under guardianship or curatorship
  • Known pathology or a health problem contraindicated with the collect of blood sample.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: PREVENTION
  • Allocation: NA
  • Interventional Model: SINGLE_GROUP
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Participants
Blood sample
Procedure: Blood sample
Blood sample

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Measure of the COVID-19 immunity of the population
Time Frame: 1 year
The COVID-19 immunity of the population will be assessed by evaluating the anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies
1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluation of the level of asymptomatic and pauci-symptomatic infections
Time Frame: 1 year
The proportion of asymptomatic and pauci-symptomatic infections will be measured in the population
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Institut Pasteur

Collaborators

Eurofins
Institut Pasteur de la Guyane
Laboratoire de biologie médicale, Institut Pasteur de la Guyane
Laboratoire de biologie médicale de Kourou, French Guiana
Laboratoire de biologie médicale du Centre hospitalier de Saint-Laurent du Maroni, French Guiana
Centres Délocalisés de Prévention et de Soins, Centre Hospitalier Andrée Rosemon de Cayenne, Frech Guiana

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

July 15, 2020

Primary Completion (ACTUAL)

September 24, 2021

Study Completion (ACTUAL)

September 24, 2021

Study Registration Dates

First Submitted

July 28, 2020

First Submitted That Met QC Criteria

July 28, 2020

First Posted (ACTUAL)

July 29, 2020

Study Record Updates

Last Update Posted (ACTUAL)

February 15, 2022

Last Update Submitted That Met QC Criteria

February 14, 2022

Last Verified

February 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2020-048

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Severe Acute Respiratory Syndrome

Clinical Trials on Blood sample

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Egypt

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe